X4 Pharmaceuticals, Inc. (NASDAQ: XFOR ) Q4 2024 Earnings Conference Call
On March 25, 2025, at 8:30 AM ET, X4 Pharmaceuticals, Inc. held its Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call. The call was hosted by Daniel Ferry, IR from LifeSci Advisors, and featured key executives of the company including Paula Ragan, CEO; Adam Mostafa, CFO; Christophe Arbet-Engels, Chief Medical Officer; and Mark Baldry, CCO.
Company Participants
- Daniel Ferry – IR, LifeSci Advisors
- Paula Ragan – CEO
- Adam Mostafa – CFO
- Christophe Arbet-Engels – Chief Medical Officer
- Mark Baldry – CCO
Conference Call Participants
- Stephen Willey – Stifel
- Ed Tenthoff – Piper Sandler
- Ayan Hussein – Cantor Fitzgerald
- Doug MacPherson – H.C. Wainwright
- David Bautz – Zacks Small-Cap Research
During the call, the X4 Pharmaceuticals team provided an update on the company’s financial results for the fourth quarter and full year 2024. The company reported a net loss of $52.3 million for the quarter, compared to a net loss of $43.5 million in the same period the previous year. For the full year, X4 Pharmaceuticals reported a net loss of $162.9 million, an increase from the net loss of $134.4 million in 2023.
Despite the increase in losses, the team expressed optimism about the company’s future prospects. They highlighted the progress made in their clinical programs, including the ongoing Phase 3 trial for X4-001 in primary hyperoxaluria type 1 (PH1) and the initiation of a Phase 2 trial for X4-1501 in primary sclerosing cholangitis (PSC).
In terms of revenue, X4 Pharmaceuticals did not report any sales during the quarter or the full year. The company continues to focus on advancing its pipeline of therapies and has not yet launched any commercial products.
Impact on Individual Investors
The financial results reported by X4 Pharmaceuticals in the Q4 2024 earnings call may not have a significant impact on individual investors in the short term. However, the progress made in the company’s clinical programs and the potential for future product launches could impact the long-term value of their investments.
Impact on the World
The advancement of X4 Pharmaceuticals’ pipeline of therapies could have a positive impact on the world by providing new treatments for rare and debilitating diseases. Primary hyperoxaluria type 1 (PH1) and primary sclerosing cholangitis (PSC) are both rare conditions that can cause significant morbidity and mortality. The successful development and commercialization of X4-001 and X4-1501 could improve the lives of patients suffering from these conditions.
Conclusion
X4 Pharmaceuticals, Inc.’s Q4 2024 earnings call provided an update on the company’s financial results and progress in its clinical programs. The company reported increased losses for the quarter and full year, but expressed optimism about the future prospects of its pipeline. The progress made in the clinical trials for X4-001 and X4-1501 could have a significant impact on individual investors and the world by providing new treatments for rare and debilitating diseases.
As always, investors are encouraged to conduct their own due diligence and consult with financial advisors before making any investment decisions.
